Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711487 | 1.00 | AHR (0.43) | AHRAPPALOX5PTGS1PTGS2 | |
| SCHEMBL4711844 | 0.86 | CHAT (0.45) | AHRAPPKDM4EALDH1A1KMT2A | |
| SCHEMBL4711845 | 0.86 | CHAT (0.45) | AHRAPPKDM4EALDH1A1KMT2A | |
| SCHEMBL4710560 | 0.85 | ALOX5 (0.49) | AHRAPPALOX5PTGS1PTGS2 | |
| SCHEMBL4710561 | 0.85 | ALOX5 (0.49) | AHRAPPALOX5PTGS1PTGS2 | |
| SCHEMBL4711138 | 0.78 | AHR (0.49) | AHRAPPPTGS1PTGS2MAPT | |
| SCHEMBL4711139 | 0.78 | AHR (0.49) | AHRAPPPTGS1PTGS2MAPT | |
| SCHEMBL4710346 | 0.78 | GRM4 (0.51) | AHRALOX5PTGS1PTGS2MAPT | |
| SCHEMBL4710348 | 0.78 | GRM4 (0.51) | AHRALOX5PTGS1PTGS2MAPT | |
| SCHEMBL4712775 | 0.78 | GRM4 (0.51) | AHRALOX5PTGS1PTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |